Vietnam is beginning to participate in one of the most important developments in modern cancer treatment as CAR T-cell therapy moves from an emerging research field towards a new generation of personalised oncology.
According to Data Bridge Market Research, Vietnam’s CAR T-Cell Therapy Treatment Market was valued at US$0.91 million in 2024 and is projected to reach US$2.32 million by 2032.
While still a very small and highly specialised market, the forecast highlights the growing potential for advanced cell and gene therapies as Vietnam strengthens its oncology, biotechnology and precision medicine capabilities.
CAR T-cell therapy — Chimeric Antigen Receptor T-cell therapy — is a form of personalised immunotherapy that genetically modifies a patient’s own T-cells to recognise and attack cancer cells.
The treatment has transformed the outlook for some patients with difficult-to-treat blood cancers, particularly where conventional treatments such as chemotherapy, targeted therapies or stem-cell transplantation have been unsuccessful.
The market currently centres primarily on:
- Leukemia
- Lymphoma
- Multiple myeloma
- Autologous CAR T-cell therapies
- Emerging allogeneic CAR T-cell therapies
- Cell processing and manufacturing
- Gene modification technologies
- Clinical research and trials
- Specialist oncology treatment centres
Globally, CAR T-cell therapy has developed into a multibillion-dollar industry. Grand View Research estimates the global CAR T-cell therapy market reached US$5.8 billion in 2025 and will grow to US$22.3 billion by 2033, representing annual growth of approximately 18.1%.
Importantly for Vietnam, Asia-Pacific is forecast to be the world's fastest-growing regional CAR T-cell therapy market, as investment in cell therapy research, manufacturing and specialist treatment centres expands.
The commercialisation of CAR-T has so far been concentrated in more developed healthcare markets because treatment is complex and expensive. Unlike conventional pharmaceuticals that can be manufactured centrally and distributed globally, many CAR T-cell treatments require a patient's own immune cells to be collected, genetically engineered, expanded in specialist facilities and then returned to the hospital for infusion.
This creates an entirely new healthcare and life sciences supply chain encompassing cell collection, apheresis, genetic engineering, cell processing, cryopreservation, cold-chain logistics, quality control, laboratory testing and specialist clinical care.
For Vietnam, developing this infrastructure will be critical to future market growth.
The country's expanding biotechnology and precision medicine capabilities provide a foundation for future adoption. Increasing investment in molecular diagnostics, genomics, clinical research and advanced laboratory technologies is gradually building the ecosystem required to support more sophisticated personalised therapies.
There is also considerable potential for technological innovation to make CAR T-cell therapy more accessible.
Next-generation allogeneic or 'off-the-shelf' CAR-T therapies are being developed using donor-derived cells rather than manufacturing an individual treatment for every patient. If successful, these approaches could shorten production times, reduce manufacturing costs and make cell therapy accessible to a much larger patient population.
Gene-editing technologies including CRISPR are also being investigated to improve CAR-T design, while automation is beginning to transform cell manufacturing. Closed-system bioprocessing, automated cell expansion and digital quality-control technologies could ultimately enable treatments to be produced more efficiently and closer to the patient.
Another major area of research is solid tumours.
Commercial CAR T-cell therapies have so far achieved their greatest success in haematological cancers, but researchers worldwide are investigating their potential against cancers including lung, breast, pancreatic and gastric cancer. Progress in these areas could dramatically expand the addressable patient population.
Vietnam-specific market research already reflects this evolution, with dedicated studies examining CAR-T applications across haematological malignancies as well as pancreatic, breast, lung and gastric cancers.
The sector also creates opportunities extending well beyond pharmaceutical companies. Development of a CAR-T ecosystem requires specialist bioprocessing equipment, laboratory automation, cell-analysis technologies, flow cytometry, reagents, cryogenic storage, cleanrooms, clinical research services, cold-chain logistics and digital manufacturing platforms.
Internationally, companies including Novartis, Gilead Sciences/Kite, Bristol Myers Squibb and Johnson & Johnson have helped establish CAR-T as a new therapeutic category, while biotechnology companies worldwide continue to develop next-generation cell therapies.
For Vietnam, the immediate market remains small. However, its importance is greater than its current value suggests.
As the country expands its oncology infrastructure and invests in biotechnology, genomics and precision medicine, CAR T-cell therapy represents part of a wider transition towards highly personalised, technology-intensive healthcare.
With Vietnam’s market projected to grow at 14.22% annually through 2032, and Asia-Pacific emerging as the fastest-growing global region, CAR-T represents an important long-term opportunity for pharmaceutical companies, biotechnology businesses, research institutions, CROs, laboratory technology providers and advanced therapy manufacturers.